Close Topic OptionsBone loss after denosumab, only partial protection with zoledronate. To counter the decline in BMD after denosumab treatment is discontinued, osteoporosis patients may be transitioned from denosumab to other anti-resorptives. This report investigates whether a single infusion of zoledronate might also be an effective option to prevent bone loss after long-term denosumab treatment in postmenopausal patients is discontinued. Source 7l.
TOPIC: Denosumab Treatment